{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:29:57Z","timestamp":1789140597918,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T00:00:00Z","timestamp":1213056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1038\/sj.bjc.6604430","type":"journal-article","created":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T07:58:35Z","timestamp":1213084715000},"page":"90-92","source":"Crossref","is-referenced-by-count":20,"title":["Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma"],"prefix":"10.1038","volume":"99","author":[{"given":"R","family":"Dahse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kosmehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,6,10]]},"reference":[{"key":"BF6604430_CR1","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","volume":"25","author":"M Agulnik","year":"2007","unstructured":"Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25: 3978\u20133984","journal-title":"J Clin Oncol"},{"key":"BF6604430_CR2","volume-title":"Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours","author":"L Barnes","year":"2005","unstructured":"Barnes L, Eveson W, Rei, Sidransky W (2005) Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. IARC Press Lyon: France"},{"key":"BF6604430_CR3","first-page":"45","volume":"1","author":"R Dahse","year":"2008","unstructured":"Dahse R, Berndt A, Dahse AK, Kosmehl H (2008) Two allele-specific PCR assays for screening epidermal growth factor receptor gene hotspot mutations in lung adenocarcinoma. Mol Med Reports 1: 45\u201350","journal-title":"Mol Med Reports"},{"key":"BF6604430_CR4","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","volume":"23","author":"DA Eberhard","year":"2005","unstructured":"Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, J\u00e4nne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900\u20135909","journal-title":"J Clin Oncol"},{"key":"BF6604430_CR5","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","volume":"12","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, J\u00e4nne PA (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12: 3908\u20133914","journal-title":"Clin Cancer Res"},{"key":"BF6604430_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129\u20132139","journal-title":"N Engl J Med"},{"key":"BF6604430_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.oraloncology.2006.12.012","volume":"8","author":"A Milano","year":"2007","unstructured":"Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F (2007) Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol 8: 729\u2013734","journal-title":"Oral Oncol"},{"key":"BF6604430_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinibtherapy. Science 304: 1497\u20131500","journal-title":"Science"},{"key":"BF6604430_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1525-1578(10)60569-7","volume":"7","author":"Q Pan","year":"2005","unstructured":"Pan Q, Pao W, Ladanyi M (2005) Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7: 396\u2013403","journal-title":"J Mol Diagn"},{"key":"BF6604430_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839\u2013844","journal-title":"Clin Cancer Res"},{"key":"BF6604430_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1440-1827.2007.02098.x","volume":"57","author":"Y Yatabe","year":"2007","unstructured":"Yatabe Y, Mitsudomi T (2007) Epidermal growth factor receptor mutations in lung cancers. Pathol Int 57: 233\u2013244","journal-title":"Pathol Int"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604430","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:33:37Z","timestamp":1684413217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,10]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["BF6604430"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604430","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,10]]}}}